Severe pancytopenia after leflunomide in rheumatoid arthritis.
Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug). So far, leflunomide has not been associated with severe bone marrow toxicity and pancytopenia. We report of a 62-year-old woman with a 14-year history of rheumatoid arthritis with bone marrow toxicity and reversible pancytopenia developing after treatment with leflunomide.
Auer
J
J
Hinterreiter
M
M
Allinger
S
S
Kirchgatterer
A
A
Knoflach
P
P
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D000077339:Leflunomide; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D011994:Recombinant Proteins
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007555:Isoxazoles; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000077339:Leflunomide; D000069585:Filgrastim